Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations
CNNMoney.com
Source: GLOBE NEWSWIRE
Seliciclib Kills Lung Cancer Cells Addicted to CDK2/Cyclin E; Phase 2 Study in Lung Cancer Ongoing
January 07, 2010: 12:08 PM ET
BERKELEY HEIGHTS, N.J., Jan. 7, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of two peer-reviewed journal articles...
The cancer drug cetuximab is to be made available on the NHS across the North East as a third-line treatment for patients with advanced colorectal tumours.
The decision by North of England Cancer Drug Approvals Group (NECDAG) has been made ahead of guidance from the National Institute for Health and Clinical Excellence (NICE).
NICE recently approved cetuximab as a firstline treatment as part of pre-surgery for...
Cetuximab added to neoadjuvant chemotherapy enables life-saving surgery in patients with liver lesions linked to colorectal cancer, according to a report in The Lancet Oncology.
It says that while removal of colorectal liver metastases is a potential cure, the disease has traditionally been inoperable in up to 80% of patients.
But research now shows that neoadjuvant treatment with irinotecan or oxaliplatin-based...
Survival in patients with advanced head and neck cancer is prolonged by adding cetuximab to radiation therapy, according to a report published online first in The Lancet Oncology.
It concludes that as improvement persists for up to five years, it should now be considered as a standard treatment option.
The report notes that most head and neck cancers express the epidermal growth factor receptor (EGFR), and that...
LONDON (Reuters) - Shaping the future of personalized medicine is not all about developing expensive new drugs -- it will also mean revisiting older, cheaper medicines armed with new genetic knowledge.
Recent discoveries of genetic clues as to why medicines work better in some patients than others suggests combining new tests with old drugs will be a cost-effective approach -- attractive to governments...
